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Abstract: Drug-induced parkinsonism (DIP) has been known for >60 years. It is the second 
leading cause of parkinsonism, but still underdiagnosis is likely to influence reported incidence 
figures. Since DIP is clinically undistinguishable from Lewy-body Parkinson’s disease, any new 
case of parkinsonism should prompt the search for an offending antipsychotic, hidden neuro-
leptic, or nonneuroleptic agent that may produce DIP. DIP is reversible upon drug withdrawal in 
most cases. There is no consensus regarding the duration of the recovery period to allow motor 
signs to fully remit in order to confirm the diagnosis of DIP following removal of the causative 
agent, but a drug-free interval of at least 6 months is generally recommended. Interestingly, up 
to 30% of DIP cases may show persisting or worsening motor signs beyond 6 months follow-
ing drug withdrawal or adjustment, due to complex postsynaptic and presynaptic factors that 
may variably interact to negatively influence nigrostriatal dopamine transmission in a so-called 
“double-hit” hypothesis. The condition significantly impacts on quality of life and increases the 
risks of morbidity and mortality. Management is challenging in psychiatric patients and requires 
a team approach to achieve the best outcome.
Keywords: neuroleptic drugs, extrapyramidal side effects, second generation antipsychotics, 
calcium channel blockers, valproic acid, tetrabenazine
Introduction
In view of its prevalence and expected reversibility upon drug withdrawal, drug-
induced parkinsonism (DIP) has drawn sustained interest for >60 years. Its causative 
mechanisms and clinical similarity with Lewy-body Parkinson’s disease (PD) have 
contributed to our understanding of the latter condition and to the discovery of oral 
levodopa as symptomatic replacement therapy.1 Although its prevalence is in part 
related to the aging of the population and expanded polypharmacy,2–4 an individual 
variation in susceptibility has long been documented.
DIP was initially described in 1954 by Bergouignan and Régnier5 and Steck6 in 
patients treated with chlorpromazine and reserpine, setting aside first-generation clas-
sical antipsychotic drugs and monoamine depleters as high-risk offenders. The list of 
drugs associated with DIP has grown ever since, to extend to gastrointestinal prokinet-
ics, calcium channel blockers, modern atypical antipsychotics, and antiepileptic drugs 
that impair dopamine function directly or indirectly.1 Many cases are serious enough 
to be spontaneously reported to sanitary agencies.7 The condition is not reversible in 
at least 10% of cases and carries a risk of morbidity and mortality particularly in the 
elderly,8 especially if neuroleptic malignant syndrome (NMS) develops. Clinicians 
must remain wary of its development and manage it diligently.
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The Diagnostic and Statistical Manual of Mental Disorders, 
fifth edition (DSM-V),9 defines DIP as the presence of rest-
ing tremor, muscular rigidity, akinesia, or bradykinesia, 
developing within a few weeks of starting or raising the 
dosage of a medication (typically a neuroleptic) or after 
reducing the dosage of an antiparkinsonian agent. In this 
definition, the presence of bradykinesia is not mandatory, in 
contrast to the conventional definition of the parkinsonian 
syndrome (PS) proposed in the UK Parkinson’s Disease 
Society Brain Bank (UKPDSBB, Step 1) clinical diagnostic 
criteria.10 The absolute symmetry of the motor signs is not 
part of the DSM-V definition, but strictly unilateral signs are 
unusual in DIP (as detailed in Clinical presentation section). 
Lack of standard criteria for DIP and misdiagnosis rate 
undoubtedly have a significant impact on epidemiological 
data. Several scales are available to document DIP, and 
the most widely used, the Simpson–Angus Scale, largely 
excludes bradykinesia as a requirement, shifting emphasis 
on rigidity.11 Using the DSM classification, Simpson–Angus 
Scale, and UKPDSBB Step 1 criteria for PS identification 
in a group of older adults medicated for chronic schizophre-
nia, the prevalence of PS was 62.5%, 87.5%, and 39.3%, 
respectively.12 In a single academic center, only one of 24 
patients with DIP had been properly diagnosed prior to 
referral.13 The reasons for underdiagnosis are several-fold, 
including lack of recognition or attribution of the clinical 
presentation to PD or the mental illness (as apathy, depres-
sion, catatonia, psychogenic condition). In wrongly ascribed 
cases, the drug profile may inadequately be deemed inoffen-
sive (eg, low-dose classical antipsychotics, use of atypical 
antipsychotics in monotherapy, or hidden neuroleptics). In 
contrast to young patients, people over age 50 years with 
declining dopamine D2 receptors density may display DIP 
with estimated D2 receptor occupancy levels <80% in the 
putamen assessed by positron emission tomography, and 
a daily dose of risperidone as low as 0.58 mg can achieve 
50% maximal receptor occupancy.14 In other missed cases 
of DIP, the motor signs may have been mild and asymptom-
atic, unilateral or asymmetric, or delayed in onset or offset. 
According to the DSM criteria, DIP must become appar-
ent within a few weeks of a change in antipsychotic drug 
treatment, but there are exceptions. With central dopamine 
antagonists, most DIP cases develop within 3 months,15,16 
but drug exposure up to 12 months may be necessary in the 
case of calcium channel blockers,16 even longer in valpro-
ate users.17 There is no consensus regarding the duration 
of the recovery period to allow motor signs to fully remit 
and confirm the diagnosis of DIP following removal of the 
causative agent, but a drug-free interval of at least 6 months 
is generally recommended.18 In 17 DIP patients studied ret-
rospectively, ten achieved complete remission after a mean 
(range 2–19 months) interval of 10 months.13
This proof of reversibility is impractical to fulfill in many 
psychiatric patients who cannot withdraw their medication 
easily. Of note, some reversible DIP cases may still show 
Lewy-body pathology at autopsy to raise a diagnosis of 
unmasked PD.19,20
Keeping these caveats in mind, it should come as no 
surprise that the prevalence of DIP is variable between stud-
ies and highly dependent on the proportion of older adults 
in the population under study. In the EUROPARKINSON 
Collaborative Study, DIP was estimated to contribute to 5% 
of all cases of PS in Europe.21 The prevalence in patients 
treated with classical antipsychotics was reported long 
ago to vary between 4%15 and 40%,22 making comparisons 
between first- and second- or third-generation antipsy-
chotics difficult. In population studies, DIP is generally 
considered the second leading cause of PS with 22% 
(door-to-door survey in central Spain),23 20% (Rochester 
Epidemiology Project),18 and 37% (Bambuí study)4 of all 
cases of parkinsonism. In tertiary care movement disor-
der clinics, the proportion of PS attributed to DIP varies 
between 4% and 10%.13,24 A preponderance of women is 
often reported, attributed to drug dosing or interaction 
issues or hormonal influences.15,16,18,25–28 In addition to old 
age and female sex, commonly accepted patient-related 
risk factors for DIP (Table 1) include preexisting extrapyra-
midal disorder,29 concomitant brain damage and atrophy,30 
dementia,29,31 HIV infection,32 severe psychiatric disease,33 
severe unexplained hyposmia,34,35 and familial PS,36 while 
drug-related risk factors include drug potency and dosing 
maximizing striatal dopamine D2 receptor occupancy in 
numbers and constancy.




Preexisting extrapyramidal disorder 29
Brain damage and atrophy 30
Dementia 29,31
HIV infection 32
Severe psychiatric disease 33
Severe unexplained hyposmia 34,35
History of familial parkinsonism 36
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In a group of 67 patients with intellectual disability, DIP 
did not correlate with overt brain damage.37 Dopamine recep-
tor gene variations seem uninvolved.38
Drugs
A strong knowledge of all drugs producing PS is important 
to raise suspicion about the disorder (Table 2). Many drug 
classes are implicated, and clinicians should know about the 
drugs carrying a risk of DIP in their own field of practice 
in order to advise and monitor patients under treatment 
adequately. Drugs associated with DIP may be classified as 
neuroleptic versus nonneuroleptic, according to their propen-
sity for causing PS or in terms of the pathogenic mechanism 
of interference of dopamine neurotransmission.1,2
Table 2 Offending agents causing DIP
Class Drugs Risk

























 Quetiapine (low-to-moderate dosage) Low
 Clozapine (low-to-moderate dosage) Low
Neuroleptics Phenothiazine derivatives Intermediate to high
 Prochlorperazine
 Promethazine










 Gastroprokinetic Heteroarylpiperidine Low
 Domperidone
 Monoamine depleters Tetrabenazine High
Reserpine
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Centrally acting dopamine receptor antagonists accounted for 
nearly half of all DIP cases in one pharmacovigilance center 
collecting spontaneous reports.16 Typical, first-generation 
antipsychotics with high affinity for dopamine D2 recep-
tors constitute a distinct class, including phenothiazines 
(eg, chlorpromazine, levomepromazine, thioridazine, per-
phenazine, fluphenazine), thioxanthenes (eg, flupentixol, 
thiothixene, zuclopenthixol), diphenylbutylpiperidines (eg, 
pimozide), dibenzoxazepines (eg, loxapine or its metabolite 
amoxapine), and butyrophenones (eg, haloperidol). Their 
risk is likely influenced by their antimuscarinic properties. 
Several second- and third-generation atypical antipsychotics 
also cause DIP or may unmask and exacerbate PD.39
Causative agents mainly include olanzapine, risperidone, 
and aripiprazole, drugs also associated with the development 
of restless legs syndrome. Well-known exceptions include 
low-to-moderate doses of the atypical drugs quetiapine and 
clozapine commonly used safely in PD.40–42
Neuroleptics
Besides antipsychotics, other dopamine receptor-blocking 
agents are well known to induce DIP. Phenothiazine 
derivatives (eg, prochlorperazine, promethazine, and first-
generation H1 antihistamines such as hydroxyzine, alime-
mazine, and aceprometazine) and benzamide substitutes 
(eg, metoclopramide, sulpiride, clebopride, veralipride) 
used for the relief of nausea, vertigo, or post-menopausal 
syndrome carry an intermediate-to-high risk of producing 
DIP. Metoclopramide has a great capacity to accumulate in 
the substantia nigra, even more so in Alzheimer’s disease 
tissues.43 The gastroprokinetic drug domperidone, which 
displays strong affinity for dopamine D2 receptors, does not 
normally cross the blood–brain barrier effectively to block 
central dopamine transmission.
Nonneuroleptic agents
Drugs interfering with central catecholamines vesicular stor-
age (tetrabenazine, reserpine) or synthesis (α-methyldopa) 
Class Drugs Risk
 Calcium channel antagonists Flunarizine, cinnarizine High
Diltiazem, verapamil Low





Selective serotonin reuptake inhibitors Intermediate
Serotonin norepinephrine reuptake inhibitors Intermediate
Monoamine oxidase inhibitors Low
 Moclobemide
 Phenelzine
 Inorganic ion Lithium Intermediate
 Anticonvulsants Valproic acid Intermediate
Phenytoin










 Antiviral (acyclovir, vidarabine, antiretrovirals)
 Antifungal (amphotericin B)
Hormones
 Thyroxine
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are regarded as high-risk offenders for DIP. Other drugs are 
in the high-risk category of drugs liable to produce DIP, 
particularly, the calcium channel antagonists flunarizine and 
cinnarizine, two drugs bearing a piperazine nucleus display-
ing dopamine receptor blockade properties and affecting 
presynaptic dopamine storage and release mechanisms.44 
Two decades ago, they were leading offending drugs in 
Japan45 and Spain.27 In comparison, the risk is much lower 
with other cardiotropic calcium channel antagonists such as 
verapamil and diltiazem, incriminated in a few DIP reports. 
This may be due to disordered calcium homeostasis affecting 
vesicular dopamine storage and release and/or to dopamine 
receptor-blocking properties. Lithium and anticonvulsant 
drugs (valproic acid in particular and phenytoin) convey 
an intermediate risk. Lithium adverse motor events may 
be due to a number of effects, including inhibition of the 
enzyme glycogen synthase kinase-3 shared with neurolep-
tics. Chronic lithium administration in older adults has been 
associated with a higher incidence of antiparkinsonian agent 
cotreatment.46 DIP has been observed in up to 6% of chronic 
valproate users, representing a tenfold rise in PS compared 
to the general population.47
Lower estimates in the order of 1.37% have also 
been documented in patients under valproate for 2.5–
10 months.48 Diagnosis is difficult due to the insidious 
onset and highly variable treatment interval before motor 
manifestations emerge, extending to years of valproate 
exposure in some cases. Patients may even respond to 
levodopa.17 The underlying molecular mechanisms remain 
elusive, possibly involving mitochondrial dysfunction 
and impaired oxidative phosphorylation.49 Serotonergic 
(5-HT) antidepressants have long been associated with an 
intermediate risk of DIP (8%),16 either in monotherapy or 
with concomitant medications (antipsychotics in particu-
lar). Reported cases have involved all classes.50,51 These 
medications do not block postsynaptic dopamine recep-
tors but have been shown to decrease striatal dopamine 
concentrations in animal studies.52 Combination of the 
antidepressant with an atypical antipsychotic blocking 
5-HT2A receptors is not preventive and, to the contrary, 
may even increase the risk of DIP. Pharmacokinetic interac-
tion at the level of CYP450 metabolism may contribute to 
raise plasma antipsychotic concentrations.51 Interestingly, 
antidepressants have also caused or aggravated restless 
legs syndrome. Miscellaneous nonneuroleptic drugs have 
been associated with a low risk of DIP: antiarrhythmics 
(amiodarone, procaine), acetylcholinesterase inhibitors, 
antibacterial (rifampicin), antiviral (acyclovir, vidarabine, 
antiretrovirals), and antifungal (amphotericin B) antibiot-
ics, and hormones (thyroxine).1,2,16 The thiazolidinedione 
derivative pioglitazone, a peroxisome proliferator-activated 
receptor-gamma and -alpha receptor agonist, has been 
reported to negatively have an impact on the motor ben-
efit derived from levodopa in a primate model of parkin-
sonism,53 but no report of DIP or aggravation of motor 
symptoms in PD subjects under oral hypoglycemic agents 
has been published. Anticancer agents generally do not 
interact with dopamine receptors.54 Methotrexate has been 
shown to reduce brain dopamine levels in rats,55 but no DIP 
cases have been reported to date. The oral 5-fluorouracil 
prodrug capecitabine reportedly caused an acute dystonic 
reaction,56 but no DIP. Thalidomide worsened PD in one 
case.57 Tamoxifen did not worsen motor function in animal 
PD models, while relieving levodopa-induced dyskinesia.58
Diagnosis and management
Clinical presentation and associated 
features
It cannot be emphasized enough that DIP is clinically similar 
to PD, although strictly unilateral motor signs occur in only 
4% of DIP cases.59 A subacute onset as mentioned in the 
DSM criteria and typically bilateral signs from the outset 
raise a suspicion of DIP, but signs are reportedly symmetric 
in 61% of patients.59 In another series of 26 autopsy-lacking 
consecutive patients, motor signs were found asymmetric 
on the Webster rating scale in 14 (54%) cases.60 Thus, asym-
metric PS is part of the DIP spectrum and does not neces-
sarily represent underlying PD. Resting tremor is common 
particularly in the upper limbs (up to 60% in one series15) 
but occasionally restricted to the lower lip and jaw (so-called 
“rabbit syndrome”). An action tremor in both hands may be 
observed alone or in association with resting tremor. Axial 
involvement (postural instability, gait disturbance) depends 
on the severity of the presentation and comorbid brain dam-
age. Slowing of gait is frequent, but freezing is unusual. 
Almost one-half of DIP cases display additional signs of 
tardive dyskinesia or akathisia.13,60 Pisa syndrome may also 
be seen, but its frequency is unclear.
In recent years, nonmotor features have been examined 
with the objective to distinguish DIP from PD. Anosmia and 
rapid eye movement sleep behavior disorder are not typical 
of DIP.34,61 Abnormal olfactory testing in DIP correctly pre-
dicted those subjects displaying persistent signs after drug 
withdrawal35 or abnormal 123I-metaiodobenzylguanidine 
(sympathetic neuron imaging ligand) cardiac scintigraphy 
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Rapid eye movement sleep behavior disorder is reported in 
15%–60% of PD patients and is suggestive of the diagnosis, 
although it may be triggered or aggravated by various anti-
depressants or acetylcholinesterase inhibitors.62 Autonomic 
complaints, including constipation and urinary and sexual 
dysfunction, are more common in PD than in DIP35,63 and 
relatively more frequent in persistent DIP than in reversible 
DIP.63 The prevalence of restless legs syndrome in DIP rela-
tive to PD is unknown.
Approach
Prevention is the best approach to avoid the acute as well as 
long-term complications that may occur with all neuroleptic 
drugs, particularly in subjects at greater risk (Table 1). The 
indications for antipsychotic drug prescription have broad-
ened tremendously within the last 20 years, in children and in 
adults alike. In institutionalized elderly with dementia living 
in Ontario (Canada), the rate of prescription of antipsychotics 
used for behavioral management has been steadily over 30% 
in the last decade.64 In general, the indication for psychotropic 
drug dispensing should be reevaluated periodically, and in 
the case of symptomatic DIP, the drug should be discontin-
ued whenever possible, a recommendation admittedly more 
easily applicable in nonpsychotic patients. For those who 
must be kept on antipsychotic drug treatment, prescribers 
must be aware that polypharmacy with psychotropic drug 
combinations may raise the risk of DIP due to unanticipated 
pharmacodynamic and/or pharmacokinetic factors. A change 
in drug class to a low-dose atypical agent, ideally  quetiapine 
or clozapine, would offer the best chance to reverse the 
condition and facilitate management in the long run. In the 
event, DIP remains symptomatic; a team approach with the 
treating psychiatrist and individualized treatment should be 
proposed, taking into account the patient age, the severity of 
the motor condition, and impact on quality of life. Prescribing 
antiparkinsonian medications may threat the underlying psy-
chopathology and cognition or exacerbate tardive dyskinesia. 
The clinical response highly depends on the robustness of 
the antipsychotic drug regime left in place for maintenance 
therapy. Thus, mild DIP is probably best left untreated. For 
the others, an anticholinergic drug or amantadine may be used 
in individuals under or over 60 years of age, respectively.65 
Levodopa may be added but reported benefit is variable and 
often modest,60 but those with valproate-induced parkinsonism 
may respond.17 Dopamine agonists have also been used,66 but 
detailed studies regarding tolerability are lacking. Physical 
therapy should be proposed particularly in those with disor-
dered posture and gait.
Other clinical issues
Persistent parkinsonism following 
neuroleptic exposure
Up to 30% of DIP cases may show persistent or worsening 
motor signs beyond 6 months following drug withdrawal or 
adjustment.67–69 In a French elderly cohort of 2,991 noninstitu-
tionalized individuals, neuroleptic exposure increased 3.2-fold 
the risk to develop probable PD.70 The risk was significant for 
benzamides and the calcium channel blockers flunarizine and 
cinnarizine. The estimated population-attributable fraction of 
PD associated with drug exposure suggested that avoidance of 
drug exposure would yield a 21.7% reduction in the number 
of new cases of PD. In the last 15 years, studies using single 
photon emission computed tomography and dopamine trans-
porter ligands have examined the integrity of the nigrostriatal 
dopamine terminals in DIP, revealing reduced binding capac-
ity in >40% of cases.71 The underlying pathogenic explanation 
for these results is lacking, since several autopsy cases of DIP 
patients under long-term antipsychotic drugs have shown no 
significant substantia nigra pathology.19,20 Thus, postsynaptic 
and presynaptic factors may variably interact to influence 
nigrostriatal dopamine transmission and contribute to persis-
tent DIP in the context of chronic neuroleptic exposure. In a 
recent review, this “double-hit” hypothesis was proposed to 
involve drug-induced neurotoxic cell death with inhibition of 
the mitochondrial respiratory chain, free radicals production, 
and lack of trophic support.72 Further studies are required to 
shed light on the mechanisms at play.
Neuroleptic malignant syndrome
Parkinsonism as part of the NMS is an infrequent drug side 
effect, with prevalence estimates averaging 0.991 cases per 
thousand people.73
Rigidity typically coexists with fluctuating delirium, 
fever, and dysautonomia and is associated with a rise in cre-
atine phosphokinase (usually >1,000 IU/L) and white blood 
cell count in most cases.74 Like DIP, NMS commonly arises 
within the first few days or months following drug initiation 
or upward titration, but it can occur at any time point during 
exposure. All neuroleptics may trigger NMS, and high dosing 
as well as polypharmacy (combination of antipsychotics or 
adjunct therapy with lithium or carbamazepine) constitutes 
pharmacological risk factors, whereas environmental factors 
include physical restraint and dehydration. Profoundly altered 
dopamine transmission due to extensive D2 receptor occu-
pancy in the basal ganglia75 and hypothalamus (disturbing 
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are thought to contribute, but current knowledge on precise 
mechanisms is lacking. Prompt recognition and withdrawal 
of the offending drug are important to prevent complications 
and mortality. Supportive treatment and use of dantrolene and 
dopamine agonists are common practice.76 Other agents such 
as amantadine, levodopa, and benzodiazepines have been 
tested. Dantrolene should be stopped as soon as possible, 
and the dopamine agonist maintained for 10 days (if harmful 
neuroleptic oral) or 2–3 weeks (if harmful neuroleptic depot). 
Reintroducing an antipsychotic may be considered at least 
2 weeks after clinical recovery.
Conclusion
The motor features of DIP are clinically indistinguishable from 
Lewy-body PD. Thus, DIP requires a high index of suspicion 
and knowledge of the diverse offending drugs in order to be 
managed effectively. The condition significantly impacts on 
quality of life and increases the risks of morbidity and mortal-
ity. It is more complex than heretofore believed, with acute and 
chronic pictures documented and a variable interplay between 
nigrostriatal presynaptic and postsynaptic mechanisms impli-
cated in different patients. Nonmotor features such as anosmia 
and cardiac denervation examined by 123I-metaiodobenzylgua-
nidine scintigraphy may distinguish pure reversible DIP from 
PD. Autopsy findings in reversible or irreversible DIP have 
shown Lewy-body midbrain pathology and neuronal loss in a 
fraction of cases only, leaving many cases unexplained. DIP 
management is challenging and requires a team approach with 
the treating psychiatrist to achieve the best outcome.
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